Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Dupilumab reduces COPD exacerbations and Type 2 inflammation biomarkers, with strongest benefit in patients with high ...

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...

Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...

Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an ...

Patients with asthma and allergic bronchopulmonary aspergillosis experienced improvements with dupilumab, according to data ...

Both indoor and outdoor air quality impact chronic obstructive pulmonary disease (COPD), which opens up a large avenue to work with patients to improve their outcomes.For COPD patients, the adage ...

Dupixent®, or dupilumab, was the first biologic medicine approved for COPD in the U.S., and targets IL-4 and IL-13 signaling, which are two of the key immune molecules involved in a type 2 ...

Approval marks the first new treatment approach for COPD in more than a decade in Japan and the sixth approved indication for chronic diseases with underlying type 2 ...

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD) ...